LINEAGE CELL THERAPEUTICS IN (LCTX) Stock News

NYSEARCA:LCTX - NYSE Arca - US53566P1093 - Common Stock - Currency: USD

1.02 -0.01 (-0.97%)

After market: 1.021 +0 (+0.1%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LCTX Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Chartmill

News Image

Lineage Cell Therapeutics Inc. (NYSEARCA:LCTX) Reports Q2 2025 Revenue Beat but Wider Loss

2 days ago - By: The Motley Fool

Lineage Cell Revenue Doubles in Q2

2 days ago - By: Zacks Investment Research - Mentions: BFRI

Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates

2 days ago - By: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

3 days ago - By: Benzinga

A Peek at Lineage Cell Therapeutics's Future Earnings

8 days ago - By: Zacks Investment Research - Mentions: NUVB

Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates

8 days ago - By: Zacks Investment Research - Mentions: BKD

Brookdale Senior Living (BKD) Reports Q2 Loss, Misses Revenue Estimates

10 days ago - By: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

11 days ago - By: Lineage Cell Therapeutics, Inc.

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

2 months ago - By: Benzinga - Mentions: SANA

Two Biotech Stocks Poised For Big Moves On Monday

2 months ago - By: Lineage Cell Therapeutics, Inc.

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

2 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

3 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

3 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Zacks Investment Research - Mentions: EDIT

Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

3 months ago - By: Lineage Cell Therapeutics, Inc.

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

4 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

4 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

4 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

5 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

5 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

6 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

6 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

7 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

7 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Issues Letter to Stockholders

9 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

9 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

9 months ago - By: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update